Low-dose aspirin inhibits platelet-induced contraction of the human isolated coronary artery: A role for additional 5-hydroxytryptamine receptor antagonism against coronary vasospasm?

Circulation

Volumn 89, Issue 2, 1994, Pages 623-629

  Bax, Willem A ^a   Renzenbrink, Gerbert J ^a   Van Der Linden, Ellen A ^a   Zijlstra, Freek J ^a   Van Heuven Nolsen, Dicky ^b   Fekkes, Durk ^a   Bos, Egbert ^a   Saxena, Pramod R ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

5 hydroxytryptamine; aspirin; thromboxane

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; 7 [3 [(2 HEPTANAMIDOACETAMIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ACETYLSALICYLIC ACID; KETANSERIN; PROSTAGLANDIN E2; SEROTONIN; SEROTONIN RECEPTOR; THROMBOXANE A2; THROMBOXANE A2 RECEPTOR;

ARTICLE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; RECEPTOR BLOCKING; THROMBOCYTE;

EID: 0028097859     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.89.2.623     Document Type: Article

References (40)

1. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
2. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Daví G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985;6:1177-1184.
3. Förstermann U, Mügge A, Bode SM, Frölich JC. Response of human coronary arteries to aggregating platelets: importance of endothelium-derived relaxing factor and prostanoids. Circ Res. 1988;63:306-312.
4. Yang Z, Stulz P, Von Segesser L, Bauer E, Turina M, Lüscher TF. Different interactions of platelets with arterial and venous coronary bypass vessels. Lancet. 1991;337:939-943.
5. Weksler BB, Pett SB, Alonso D, Richter RC, Stelzer P, Subramanian V, Tack-Goldman K, Gay WA. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med. 1983;308:800-805.
6. 1α excretion in healthy subjects. Thromb Res. 1987;45:355-361.
7. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990;336:827-830.
8. Nyman I, Larsson H, Wallentin L, The Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. Lancet. 1992;340:497-501.
9. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325: 1261-1266.
10. Cohen RA, Shepherd JT, Vanhoutte PM. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science. 1983;221:273-274.
11. Hourani SMO, Cusack NJ. Pharmacological receptors on blood platelets. Pharmacol Rev. 1991;43:243-298.
12. 2, and ADP. Circulation. 1989;79: 698-705.
13. Van den Berg EK, Schmitz JM, Benedict CR, Malloy CR, Willerson JT, Dehmer GJ. Transcardiac serotonin concentration is increasing in selected patients with limiting angina and complex coronary morphology. Circulation. 1989;79:116-124.
14. 2 levels in patients with classic and variant angina pectoris. Circulation. 1981;64:1107-1115.
15. De Boer AC, Turpie AGG, Butt RW, Johnston RV, Genton E. Platelet release and thromboxane synthesis in symptomatic coronary artery disease. Circulation. 1982;66:327-333.
16. Zijlstra FJ, Vincent JE, Mol WM, Hoogsteden HC, Van Hal PThW, Jongejan RC. Eicosanoid levels in bronchoalveolar lavage fluid of young female smokers and non-smokers. Eur J Clin Invest. 1992;22:301-306.
17. Ginsburg R, Bristow MR, Davis K, Dibiase A, Billingham ME. Quantitative pharmacologic responses of normal and atherosclerotic isolated human epicardial coronary arteries. Circulation. 1984;69:430-440.
18. Bossaller C, Habib GB, Yamamoto H, Williams C, Wells S, Henry PD. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary artery and rabbit aorta. J Clin Invest. 1987;79: 170-174.
19. Schumacher WA, Heran CL, Allen GT, Ogletree ML. Leukotrienes cause mesenteric vasoconstriction and hemoconcentration in rats without activating thromboxane receptors. Prostaglandins. 1989;3:335-344.
20. 2-receptor blockade: a randomized, double-blind, placebo-controlled trial. Circulation. 1991;84:1568-1580.
21. Gresele P, Deckmyn H, Nenci GG, Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol Sci. 1991;12: 158-163.
22. Fiddler GI, Lumley P. Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers: a review. Circulation. 1990;81(suppl I):I-69-I-78.
23. 2 receptor activation. Eur J Pharmacol. 1989;161:91-94.
24. Toda N, Okamura T. Comparison of the response to 5-carboxamidotryptamine and serotonin in isolated human, monkey and dog coronary arteries. J Pharmacol Exp Ther. 1990;253:676-682.
25. De Cateriina R, Carpeggiani C, L'Abbate A. A double-blind, placebo-controlled study of ketanserin in patients with Prinzmetal's angina: evidence against a role for serotonin in the genesis of coronary vasospasm. Circulation. 1984;69:889-894.
26. Hoyer D. 5-Hydroxytryptamine receptors and effector coupling mechanisms in peripheral tissues. In: Fozard JR, ed. The Peripheral Actions of 5-Hydroxytryptamine. Oxford, UK: Oxford University Press; 1987:72-99.
27. Hillis LD, Lange RA. Serotonin and acute ischemic heart disease. N Engl J Med. 1991;324:688-690.
28. Saxena PR, Villalon CM. 5-HT, a chameleon in the heart. Trends Pharmacol Sci. 1991;12:223-227.
29. 1D-like receptors, and a comparison with grafted veins. Naunyn Schmiedebergs Arch Pharmacol. 1992;345:500-508.
30. McFadden EP, Bauters C, Lablanche JM, Leroy F, Clarke JG, Henry M, Schandrin C, Davies GJ, Maseri A, Bertrand ME. Effect of ketanserin on proximal and distal coronary constrictor responses to intracoronary infusion of serotonin in patients with stable angina, patients with variant angina, and control patients. Circulation. 1992;86:187-195.
31. Altman JD, Dulas D, Pavek T, Bache RJ. Effect of aspirin on collateral blood flow. Circulation. 1993;87:583-589.
32. Haslam RJ, McClenaghan MD. Measurement of circulating prostacyclin. Nature. 1981;292:364-366.
33. Chester AH, O'Neil G, Moncada S, Tadjkarimi S, Yacoub M. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet. 1990;336:897-900.
34. Kaul S, Padgett RC, Waack BJ, Brooks RM, Heistad DD. Effect of atherosclerosis on responses of the perfused rabbit carotid artery to human platelets. Arterioscler Thromb. 1992;12:1206-1213.
35. Shimokawa H, Vanhoutte PM. Impaired endothelium-dependent relaxation to aggregating platelets and related vasoactive substances in porcine coronary arteries in hypercholesterolemia and atherosclerosis. Circ Res. 1989;64:900-914.
36. De Clerck F, Van Nueten JM. Platelet-mediated vascular contractions, inhibition by flunarizine, a calcium-entry blocker. Biochem Pharmacol. 1983:32:765-771.
37. 2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation. 1987;76:952-959.
38. Yao S-K, Benedict CR, Rosolowsky M, Rosolowsky M, McNatt J, Falinska B, Campbell WB, Buja LM, Willerson JT. Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis. J Mol Cell Cardiol. 1991;23:473-482.
39. 2 receptors in vascular smooth muscle. Br J Pharmacol. 1991; 102:203P. Abstract.
40. 2 and 5-hydroxytryptamine receptor subtypes in human coronary arteries. Circulation. 1993;87:874-880.